Key Takeaways
- Academic and clinical customers do not separate Medical Affairs from Commercial in their experience of the company.
- Shared market understanding and evidence priorities prevent conflicting narratives.
- Centers of Excellence engagement should begin before promotional intensity.
- Launch governance must give both functions clear decision rights and escalation paths.
One of the fastest ways to weaken a biotechnology launch is to allow Medical Affairs and Commercial to operate from different descriptions of the market.
Physicians evaluate one organization. If scientific engagement, educational priorities and commercial execution conflict, credibility erodes. Integrated preparation is therefore a launch requirement—especially for first launches and rare disease markets.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
